Publications

BibTex format

@article{Riggioni:2020:10.1111/all.14449,
author = {Riggioni, C and Comberiati, P and Giovannini, M and Agache, I and Akdis, M and Alves-Correia, M and Antó, JM and Arcolaci, A and Kursat, Azkur A and Azkur, D and Beken, B and Boccabella, C and Bousquet, J and Breiteneder, H and Carvalho, D and De, Las Vecillas L and Diamant, Z and Eguiluz-Gracia, I and Eiwegger, T and Eyerich, S and Fokkens, W and Gao, Y-D and Hannachi, F and Johnston, SL and Jutel, M and Karavelia, A and Klimek, L and Moya, B and Nadeau, K and O'Hehir, R and O'Mahony, L and Pfaar, O and Sanak, M and Schwarze, J and Sokolowska, M and Torres, MJ and van, de Veen W and van, Zelm MC and Wang, DY and Zhang, L and Jiménez-Saiz, R and Akdis, CA},
doi = {10.1111/all.14449},
journal = {Allergy},
pages = {2503--2541},
title = {A compendium answering 150 questions on COVID-19 and SARS-CoV-2.},
url = {http://dx.doi.org/10.1111/all.14449},
volume = {75},
year = {2020}
}

Download

RIS format (EndNote, RefMan)

TY  - JOUR
AB  - In December 2019, China reported the first cases of the coronavirus disease 2019 (COVID-19). This disease, caused by the severe acute respiratory syndrome-related coronavirus 2 (SARS-CoV-2), has developed into a pandemic. To date it has resulted in ~6.5 million confirmed cases and caused almost 400,000 related deaths worldwide. Unequivocally, the COVID-19 pandemic is the gravest health and socio-economic crisis of our time. In this context, numerous questions have emerged in demand of basic scientific information and evidence-based medical advice on SARS-CoV-2 and COVID-19. Although the majority of the patients show a very mild, self-limiting viral respiratory disease, many clinical manifestations in severe patients are unique to COVID-19, such as severe lymphopenia and eosinopenia, extensive pneumonia, a "cytokine storm" leading to acute respiratory distress syndrome, endothelitis, thrombo-embolic complications and multiorgan failure. The epidemiologic features of COVID-19 are distinctive and have changed throughout the pandemic. Vaccine and drug development studies and clinical trials are rapidly growing at an unprecedented speed. However, basic and clinical research on COVID-19-related topics should be based on more coordinated high-quality studies. This paper answers pressing questions, formulated by young clinicians and scientists, on SARS-CoV-2, COVID-19 and allergy, focusing on the following topics: virology, immunology, diagnosis, management of patients with allergic disease and asthma, treatment, clinical trials, drug discovery, vaccine development and epidemiology. Over 140 questions were answered by experts in the field providing a comprehensive and practical overview of COVID-19 and allergic disease.
AU  - Riggioni,C
AU  - Comberiati,P
AU  - Giovannini,M
AU  - Agache,I
AU  - Akdis,M
AU  - Alves-Correia,M
AU  - Antó,JM
AU  - Arcolaci,A
AU  - Kursat,Azkur A
AU  - Azkur,D
AU  - Beken,B
AU  - Boccabella,C
AU  - Bousquet,J
AU  - Breiteneder,H
AU  - Carvalho,D
AU  - De,Las Vecillas L
AU  - Diamant,Z
AU  - Eguiluz-Gracia,I
AU  - Eiwegger,T
AU  - Eyerich,S
AU  - Fokkens,W
AU  - Gao,Y-D
AU  - Hannachi,F
AU  - Johnston,SL
AU  - Jutel,M
AU  - Karavelia,A
AU  - Klimek,L
AU  - Moya,B
AU  - Nadeau,K
AU  - O'Hehir,R
AU  - O'Mahony,L
AU  - Pfaar,O
AU  - Sanak,M
AU  - Schwarze,J
AU  - Sokolowska,M
AU  - Torres,MJ
AU  - van,de Veen W
AU  - van,Zelm MC
AU  - Wang,DY
AU  - Zhang,L
AU  - Jiménez-Saiz,R
AU  - Akdis,CA
DO  - 10.1111/all.14449
EP  - 2541
PY  - 2020///
SN  - 0105-4538
SP  - 2503
TI  - A compendium answering 150 questions on COVID-19 and SARS-CoV-2.
T2  - Allergy
UR  - http://dx.doi.org/10.1111/all.14449
UR  - https://www.ncbi.nlm.nih.gov/pubmed/32535955
UR  - https://onlinelibrary.wiley.com/doi/abs/10.1111/all.14449
UR  - http://hdl.handle.net/10044/1/79932
VL  - 75
ER  -

Download

ProfessorSebastianJohnston

Contact

Assistant

Location

Summary

Citation

BibTex format

RIS format (EndNote, RefMan)